Collegium Pharmaceutical (FRA:354) Total Receivables: €197.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:354 Collegium Pharmaceutical Inc FRA:354
76 GF Score
Price €30.20
GF Value €37.50
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Total Receivables?

Collegium Pharmaceutical FRA:354 -1.95% 76 Total Receivables is €197.9 Mil as of Mar. 2026. GuruFocus rates FRA:354 with a GF Score™ of 76/100 and a GF Value™ of €37.50 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Collegium Pharmaceutical's Total Receivables for the quarter that ended in Mar. 2026 was €197.9 Mil.

Collegium Pharmaceutical Total Receivables Related Terms

Collegium Pharmaceutical Total Receivables Historical Data

* Premium members only.

The historical data trend for Collegium Pharmaceutical's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical Total Receivables Chart

Collegium Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.67 172.86 164.62 218.26 180.47

Collegium Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 211.56 184.69 199.33 180.47 197.88
FRA:354
76GF Score
Collegium Pharmaceutical Inc FRA:354
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Collegium Pharmaceutical Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €197.9 Mil mean?
Collegium Pharmaceutical (FRA:354) has a Total Receivables of €197.9 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Collegium Pharmaceutical and its competitors.
Is Collegium Pharmaceutical's Total Receivables too high?
Collegium Pharmaceutical's current Total Receivables is €197.9 Mil. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Total Receivables compare to ALVO and PAHC?
Collegium Pharmaceutical's Total Receivables of €197.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Collegium Pharmaceutical and its competitors. Collegium Pharmaceutical's current Total Receivables is €197.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (FRA:354) is currently considered Modestly Undervalued. The stock's GF Value™ is €37.50, compared to a current price of €30.20 — trading 19.5% below its estimated fair value. The current Total Receivables is €197.9 Mil. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Total Receivables is €197.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €30.20 is trading 19.5% below its estimated GF Value™ of €37.50. GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.

Key valuation signals for FRA:354:

  • Total Receivables: €197.9 Mil
  • GF Value™: €37.50 vs. price of €30.20 (19.5% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score

Get the complete analysis for FRA:354

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.20
Price
€37.50
GF Value